• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

byGursharan SohiandYuchen Dai
July 7, 2022
in Chronic Disease, Imaging and Intervention, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Plasma biomarkers, including p-tau217, were found to accurately detect cerebral changes pathognomonic for Alzheimer’s disease in this cross-sectional, multicenter study

2. Adults with Down Syndrome are at increased risk of developing Alzheimer’s disease due to over-expression of the APP

Level of Evidence Rating: 2 (Good)

Study Rundown: Down Syndrome is a genetic condition caused by a nondisjunction of chromosome 21 and presents with a range of clinical manifestations from the time of birth onwards. The APP gene is frequently overexpressed in Down Syndrome individuals and leads to an accumulation of tau protein in the brain as seen in Alzheimer’s disease. This may or may not cause a decline in function consistent with a clinical diagnosis of dementia, although the neuropathologic changes are the same. The present study sought to identify plasma biomarkers to aid in the diagnosis and prognostication of Alzheimer’s disease in patients with Down Syndrome.

In total, 300 participants with Down Syndrome (DS) and 37 of their siblings (controls) were included in this study. 212 patients were cognitively stable at baseline, 40 had mild cognitive impairment and 33 had Alzheimer’s dementia. DS patients began to develop AB-PET changes on imaging at around 35 years of age. P-tau217, GFAP and NfL plasma biomarkers were increased in the DS group as compared to non-DS siblings and titers correlated with the severity of cognitive impairment. Higher levels of tau protein in the serum were also associated with poor cognitive function as measured by the Down Syndrome mental status exam and cued recall testing.

Janelidze et al conclude that p-tau217 in the plasma is associated with cerebral tau and AB protein levels and is thus an accurate marker of Alzheimer’s disease in patients with Down Syndrome. A primary limitation of this study is the cross-sectional format which prohibits longitudinal data collection. Additionally, the clinical applicability of these findings is limited due to the practical and financial limitations of the biochemical tests performed in this study. However, this work is novel and may open new avenues for research and clinical practice in the future.

RELATED REPORTS

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

Caregivers of people with dementia may benefit from online decision aid when managing firearm access

High-sugar dietary pattern associated with increased risk of dementia

Click here to read this study in JAMA Neurology

Relevant Reading: Assessing candidate serum biomarkers for Alzheimer’s disease: a longitudinal study

In Depth: [cross-sectional study]: This cross-sectional, multi-center study, the Alzheimer’s Biomarker Consortium Down Syndrome (ABC-DS) study, enrolled participants between July 2016 and January 2019. At the time of enrollment, cognitive status was assessed as stable, mildly impaired or severely impaired (dementia) using standard clinical measurement tools. The following plasma biomarkers were assessed using immunoassay technologies previously described in the literature: p-tau217, GFAP, NfL and t-tau proteins. Additionally, PET imaging was used to assess uptake of TAU and AB proteins which correlate with structural cerebral changes.

The tau-PET signal was most prominent in the temporal region of interest on imaging amongst individuals with p-tau217 detected in the serum. The odds ratio and 95% confidence interval for each serum biomarker with temporal tau-PET activities are as follows: 2.13 (1.52-2.99) for p-tau217, 2.08 (1.49-2.89) for GFAP, 1.29 (1.06-1.57) for NfL, 1.24 (0.93-1.65) for t-tau and 1.15 (0.85-1.56) for AB42/AB40. Higher levels of plasma tau217 was associated with lower cognitive function on mental status exam (beta of -0.31, 95% confidence interval -0.40 to -0.22) and cued recall (-0.50, -0.60 to -0.40). Finally, sensitivity analysis stratifying patients by age (below 35 years) showed similar patterns of findings, although cerebral AB and tau protein load were less significant in younger patients compared to the older group.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: Alzheimer’s diseaseDown syndrometau protein
Previous Post

Life expectancy disparities have increased between ethnic groups in certain states

Next Post

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

January 7, 2025
Public Health

Caregivers of people with dementia may benefit from online decision aid when managing firearm access

October 22, 2024
Neurology

High-sugar dietary pattern associated with increased risk of dementia

July 25, 2024
Amyloid may cause distant cerebral hypometabolism in Alzheimer’s
Chronic Disease

APOE3 Christchurch heterozygosity may delay cognitive impairment in Alzheimer’s disease

June 25, 2024
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

Being overweight and obese associated with increased incidence of chronic kidney disease

Comparisons of invasive versus conservative management in chronic kidney disease in the ISCHEMIA-CKD trials

Smoking during pregnancy associated with aerobic fitness of children

Community-based and health-care based smoking cessation intervention models have similar efficacy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
  • Fecal microbiota transplantation may be more effective than vancomycin in treating primary C. difficile infection
  • Frailty scores alone may be poor predictors of intensive care admission or hospital stay duration
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.